I will do all I can to protect my patients from relapse”
The first and only FDA approved oral maintenance therapy shown to cut the risk of high-risk neuroblastoma relapse in half.
Introducing IWILFIN
For high-risk neuroblastoma patients with at least a partial response to multiagent, multimodality therapy including immunotherapy, IWILFIN may help reduce the risk of relapse1
Understanding the importance of maintenance therapy in high-risk neuroblastoma.
Learn how IWILFIN targets specific oncogenic pathways in high-risk neuroblastoma.
Explore IWILFIN’s efficacy and safety data.
IWILFIN Cares™ provides comprehensive support services to help your patients start and stay on therapy.
References:
1. IWILFIN. Prescribing information. USWM, LLC; 2023